Company intelligence / Profile preview
nChroma Bio
Boston, Massachusetts, United Statesnchromabio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead candidate CRMA-1001 has shown robust silencing of HBV biomarkers in preclinical models, potentially offering high functional cure rates for patients with chronic HBV and HDV
- Therapeutic areas
- Infectious Diseases
- Modalities
- Epigenetic editingnon-viral delivery systems
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on nChroma Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nChroma Bio.